Skip to main content

Healthy Volunteers (HV)

3
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

argenx
argenxBelgium - Zwijnaarde
1 program
1
Adimanebart IVPhase 11 trial
Active Trials
NCT07673601Recruiting52Est. Dec 2026
Vertero Therapeutics
1 program
1
VT-5006Phase 11 trial
Active Trials
NCT07310264Recruiting84Est. Sep 2026
Eilean Therapeutics
1 program
1
ZE66-0205Phase 11 trial
Active Trials
NCT07735728Not Yet Recruiting32Est. Aug 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
Eilean TherapeuticsZE66-0205
argenxAdimanebart IV
Vertero TherapeuticsVT-5006

Clinical Trials (3)

Total enrollment: 168 patients across 3 trials

A First-in-Human Study of ZE66-0205 in Healthy Volunteers

Start: Aug 2026Est. completion: Aug 202732 patients
Phase 1Not Yet Recruiting
NCT07673601argenxAdimanebart IV

A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants

Start: Jun 2026Est. completion: Dec 202652 patients
Phase 1Recruiting

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Start: Oct 2025Est. completion: Sep 202684 patients
Phase 1Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 168 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.